DRTX

Durata Therapeutics, Inc. News Headlines

$12.67
*  
0.11
 negative 
0.86%
Get DRTX Alerts
*Delayed - data as of Apr. 17, 2014 
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    DRTX After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Over 91% Chance Of Approval For MannKind And Durata Therapeutics
4/7/2014 12:00:00 PM - Seeking Alpha

Durata Therapeutics: Gains Ahead
4/2/2014 9:05:00 AM - Seeking Alpha

Adherex At ASCO, FDA Panel Backs CBST, DRTX, PRAN's IMAGINE Fails, SKBI Shines
4/1/2014 1:08:00 AM - RTT News

FDA Panel Unanimously Oks Approval For Two Antibiotics, Dalvance And Sivextro
3/31/2014 11:47:00 PM - RTT News

Durata Therapeutics Q4 Loss Widens
3/14/2014 12:23:00 PM - RTT News

Durata Therapeutics (DRTX) Jumps: Stock Rises 6.5% - Tale of the Tape
2/19/2014 10:21:01 AM - Zacks.com

Durata Therapeutics: Primed For Big Gains With March Advisory Committee Date Announced
2/13/2014 11:22:00 AM - Seeking Alpha

Antibiotic Companies To Cash In On In 2014
2/13/2014 8:30:00 AM - Seeking Alpha

Durata Progresses with Dalbavancin - Analyst Blog
12/27/2013 8:00:01 PM - Zacks.com

Durata Therapeutics Inc (DRTX) Enters Overbought Territory - Tale of the Tape
9/12/2013 7:57:40 AM - Zacks.com

Durata Therapeutics' Novel Antibiotic Makes It A Prime Takeover For 2013
7/30/2013 7:25:00 PM - Seeking Alpha

Buying Opportunity In Durata Therapeutics
6/28/2013 1:04:00 PM - Seeking Alpha

3 Speculative Healthcare Companies With High Levels Of Insider Ownership - Part III
3/26/2013 11:36:00 AM - Seeking Alpha

Trius: Topline Data From Second Phase III Trial Of Tedizolid Is Imminent
3/18/2013 8:54:00 AM - Seeking Alpha

Stephen Brozak: Changing The Way Money Is Made And Diseases Are Cured
1/25/2013 2:11:00 PM - Seeking Alpha

Durata Therapeutics: Low Floater With Near-Term Phase III Catalyst
1/9/2013 6:15:00 PM - Seeking Alpha

2 Biotech Firms To Consider In The Wake Of Positive Clinical Data
12/11/2012 3:50:00 PM - Seeking Alpha

5 Low-Debt Biotech Stocks Forecasted For Growth
9/22/2012 9:09:00 AM - Seeking Alpha

An Investment Update On Trius Therapeutics' Tedizolid
8/22/2012 10:34:14 AM - SeekingAlpha

IPO market heats up with four mid-summer deals, 11 on the calendar
7/20/2012 5:56:11 PM - Renaissance Capital

Durata Therapeutics prices IPO at $9, below the range
7/18/2012 7:32:41 PM - Renaissance Capital

5 US IPOs planned for the week of Jul 16
7/16/2012 8:00:07 AM - Renaissance Capital

Durata Therapeutics sets terms for $75 million US IPO
7/9/2012 5:14:07 PM - Renaissance Capital